跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 16 天前AI 评分33

Spyre 疗法的抗 TL1A 药物 SPY072 临床试验失败

Spyre’s arthritis misses; Ideaya ends eye cancer trial

AI 导读

Spyre Therapeutics 报告其长效抗 TL1A 药物 SPY072 临床试验失败。该试验旨在治疗自身免疫性疾病。

正文

Plus news about Unit­ed Ther­a­peu­tics.

Spyre Ther­a­peu­tics re­ports ad­di­tion­al tri­al fail­ures: The biotech said its long-act­ing an­ti-TL1A drug, co­de­named SPY072, did …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news